SecBot SecBot
PRESS-RELEASE ·Filed May 4, 2026

AXSM

Axsome Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor Auvelity's launch in Alzheimer's agitation (June 2026) as the primary near-term catalyst; revenue growth trajectory remains strong, but rising SG&A expenses and EPS miss suggest caution on margin expansion. Focus on prescription trends and payer coverage updates.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$223.70
T+0 close · May 4, 2026 · via day close
Latest settled
+1.66%
T+60 · $227.42
Vs SPY
−0.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $223.70entry
  2. T+1 · 7mo ago −0.29%α −1.08% · $223.06
  3. T+5 · 6mo ago −3.23%α −6.17% · $216.47
  4. T+20 · 6mo ago +2.93%α −2.72% · $230.25
  5. T+60 · 4mo ago +1.66%α −0.19% · $227.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but GAAP EPS of -$1.26 missed the -$0.86 consensus by 46.5% due to higher SG&A and R&D costs. The recent FDA approval of Auvelity for Alzheimer's agitation is a key catalyst, but widening losses and rising expenses temper optimism.

Key Financial Metrics

EPS
−$1.26
est −$0.86 · -46.5%
Revenue
$191.2M
est $190.7M · +0.3% · +57.3% YoY
Rating
miss
Gross Margin
92.3%

Key Facts

  • Q1 2026 net product revenue $191.2M, +57% YoY vs $121.5M
  • AUVELITY revenue $153.2M, +59% YoY; ~223,000 prescriptions written
  • SUNOSI revenue $33.9M, +34% YoY; SYMBRAVO revenue $4.1M
  • GAAP net loss $(64.5M) or $(1.26)/share vs $(59.4M) or $(1.22)/share in Q1 2025
  • FDA approved AUVELITY for Alzheimer's disease agitation in April 2026; full launch expected June 2026
  • Cash and equivalents $305.1M at March 31, 2026

Financial Impact

Revenue grew 57% YoY to $191.2M, but net loss widened to $(64.5M) from $(59.4M) due to increased SG&A and R&D spending.

revenueepsnet_loss

Risk Factors

  • SG&A expenses grew 53% YoY, outpacing revenue growth and pressuring margins
  • Net loss per share worsened to $(1.26), missing consensus by 46.5%

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3286568

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026